When injections become a realistic option

For most people with knee osteoarthritis, an injection is not the starting point — it is what a specialist considers after earlier measures have had a fair trial and fallen short.

NICE guideline NG226 sets out the clinical logic clearly. A diagnosis of knee OA can be made without imaging in adults aged 45 or over who have activity-related joint pain and morning stiffness lasting no longer than 30 minutes. No scan is needed to begin treatment. The first steps recommended by NICE and the NHS are lifestyle measures — regular exercise, weight management, and appropriate analgesia — because the evidence shows these provide meaningful symptom relief for a substantial proportion of patients.

Injections sit further along that pathway. They become a reasonable option when exercise therapy, physiotherapy, and pain management have not delivered adequate relief — not as a shortcut around rehabilitation, but as the next escalation when the groundwork has been laid.

This matters in a practical sense: arriving at a consultation having already worked through conservative options strengthens the case for injection treatment and gives the clinician a clearer picture of what the knee actually needs. Patients who are still in the early stages of conservative care are generally advised to complete that phase first.

If symptoms persist despite those efforts, an injection assessment is an appropriate next step — and the question then shifts to which type of injection suits your particular presentation.

What makes a good candidate: core eligibility criteria

Several factors tend to cluster together in patients who respond best to a knee injection — recognising them helps set realistic expectations before a consultation.

Confirmed diagnosis with imaging review. Eligibility begins with a confirmed OA diagnosis supported by X-ray or MRI. Imaging lets the clinician assess remaining joint space and the degree of cartilage wear. It is one input among several — not a verdict the patient interprets alone — but it is essential before any injection decision is made.

Enough cartilage remaining to respond. The most consistent threshold across injection types is mild-to-moderate disease: enough cartilage for the joint to respond to treatment. Patients with bone-on-bone arthritis are routinely excluded from injection trials because benefit diminishes as cartilage loss advances. A 2019 systematic review (Nicholls et al.) confirmed this pattern specifically for hyaluronic acid, and real-world outcomes data reflects the same picture for more recently introduced agents.

Symptoms that have persisted despite conservative care. Having genuinely tried exercise, physiotherapy, and analgesia — not simply attempted these briefly — is a prerequisite, not a formality. Clinically significant, ongoing pain and stiffness is what shifts injection treatment from optional to appropriate.

Realistic expectations. Injections can reduce symptoms and help maintain function; they do not regenerate cartilage or resolve OA. Patients who understand that distinction tend to report greater satisfaction with outcomes.

An independent real-world study of 269 patients (314 knees) adds specificity to these principles: older adults with mild-to-moderate disease and no poorly controlled diabetes were most likely to benefit, while those with advanced arthritis were more likely to progress to knee replacement regardless of injection type.

These factors form a cluster, not a single pass/fail gate. Each injection carries product-specific nuances, but this core framework broadly guides suitability across the range.

When an injection is unlikely to help

Not everyone who presents with knee OA pain will be a suitable candidate for injection therapy — and understanding why can be as useful as knowing who benefits.

Bone-on-bone arthritis. When cartilage loss is advanced and the joint space has largely disappeared, there is less biological substrate for an injection to support. Viscosupplementation and most other injectables rely on remaining tissue and joint architecture to produce their effect; outcomes data consistently shows that advanced disease predicts progression to knee replacement rather than durable injection benefit.

Active joint infection. This is an absolute contraindication for any intra-articular injection. Introducing a substance into an infected joint risks spreading infection and causing serious harm.

Poorly controlled diabetes. Corticosteroid injections can produce a significant, if temporary, rise in blood glucose — a particular concern where diabetes is already poorly managed. Real-world outcomes data also flags poorly controlled diabetes as a factor associated with reduced benefit from newer injectables, suggesting a broader metabolic influence on response.

Unrealistic expectations. A patient expecting complete pain elimination or indefinite relief is a clinical caution rather than a hard exclusion, but shared decision-making becomes difficult without a realistic baseline. Injections manage symptoms; they do not reverse structural disease.

Repeated corticosteroid courses. Laboratory and systematic-review evidence has raised a potential chondrotoxicity signal with high or repeated steroid doses (Wernecke et al., 2015; Dragoo et al., 2012). Clinicians factor this into decisions about frequency, particularly in younger patients who may need to preserve options over a longer horizon. The risk is proportional to dose and frequency rather than a consequence of any single injection.

What a pre-injection assessment involves

Arriving at a specialist MSK consultation prepared makes the appointment more productive — and more likely to result in a clear recommendation.

Symptom history. You will be asked how long pain has been present, how severe it is day-to-day, what aggravates or eases it, and which treatments you have already tried. This context helps the clinician judge whether the injection threshold has genuinely been reached.

Physical examination. The clinician will assess pain location, range of motion, joint stability, and any swelling. Findings from this examination help confirm the clinical picture before any treatment decision is made.

Imaging review. Current X-ray or MRI is usually required to grade remaining joint space and cartilage condition. Imaging taken several years ago may not reflect how the joint has changed since — if your most recent scan is out of date, it is worth requesting an updated one before the appointment. A consultation without current imaging is typically insufficient to proceed to an injection decision.

Discussion of realistic outcomes. The consultation should include an honest conversation about what improvement looks like for your stage of OA, how long any benefit may last, and what the next step would be if the injection does not provide adequate relief.

The injection options you may be offered

Several distinct injection types may be discussed at a specialist consultation, each with a different mechanism, evidence profile, and typical duration of effect.

Corticosteroids are the most widely used option — low cost, fast-acting, and generally well tolerated for a single course. As covered in the contraindications section above, high or repeatedly administered doses carry a potential cartilage-safety signal, so frequency is kept to a minimum where alternatives exist.

Hyaluronic acid (viscosupplementation) aims to restore the cushioning and lubricating properties of joint fluid. Evidence more consistently supports multi-injection regimens (typically two to five doses at weekly intervals) than single-injection schedules, though single-dose formulations such as Monovisc are growing in clinical use because they reduce the number of clinic visits and associated procedural risks. It is worth noting that NICE NG226 does not currently recommend viscosupplementation as standard NHS care, so access and funding vary.

Combined HA and corticosteroid injections (for example, Cingal) deliver both mechanisms in one procedure and are indicated for pain, stiffness, swelling, and restricted movement associated with OA.

Arthrosamid, a polyacrylamide hydrogel (iPAAG), is a single-injection option with a reported average symptom-relief duration of two to three years. Independent real-world data supports its use in mild-to-moderate disease; patients with advanced arthritis showed less durable benefit.

Platelet-rich plasma (PRP) remains an evolving area. Evidence is still accumulating and eligibility criteria are not yet well standardised, so it is best framed as a developing option rather than an established standard.

Questions to ask at your consultation

Taking a short list of written questions into a specialist appointment helps ensure the conversation covers what matters most to you — and signals to the clinician that you are an active participant in the decision.

• Based on my imaging and symptoms, which injection type best suits my stage of OA — and why that one rather than alternatives?
• What realistic improvement should I expect, and over what timeframe?
• How many injections might I need, and how frequently?
• What are the specific risks or side effects relevant to my health profile?
• If this injection does not provide adequate relief, what are the next steps?

A clinician who welcomes these questions is more likely to give you an honest, individualised answer than one who offers only a brief recommendation. If a question cannot be answered clearly without further imaging or test results, that itself is useful information — it tells you the assessment is not yet complete enough to proceed.